Furthermore, we tested the effect of anti-CD47 by using two different clones of anti-CD47 antibody (B6H12 and MIAP301) in vivo and the results showed that both B6H12 and MIAP301 could inhibit the progression of meningioma, which was consistent with the findings of previous study on other tumors. This evidence concerns the gene CD47 and meningioma.